logo
RFK Jr. wants everyone to use wearables. What are the benefits, risks?

RFK Jr. wants everyone to use wearables. What are the benefits, risks?

Yahoo2 days ago
Last week, Health and Human Services Secretary Robert F. Kennedy Jr. announced the agency was launching a campaign to encourage all Americans to use wearables to track health metrics.
Wearables come in the form of watches, bands, rings, patches and clothes that can be used for a variety of reasons including monitoring glucose levels, measuring activity levels, track heart health and observe sleeping patterns.
"It's a way … people can take control over their own heath. They can take responsibility," Kennedy said during a hearing of the House Subcommittee on Health. "They can see, as you know, what food is doing to their glucose levels, their heart rates and a number of other metrics as they eat it. and they can begin to make good judgments about their diet, about their physical activity, about the way that they live their lives."
He went on, "We think that wearables are a key to the MAHA agenda -- Making America Healthy Again. My vision is that every American is wearing a wearable within four years."
MORE: Fitness trackers can help monitor health for some people, but can exacerbate disordered eating for others
Digital medicine experts told ABC News that wearables do have benefits and can be used to motivate someone to increase physical activity, which could reduce the risk of poor health outcomes.
However, they said not everybody needs to have a wearable and there are some potential risks including data breaches.
Nabil Alshurafa, an associate professor in the department of preventive medicine and the department of electrical and computer engineering at Northwestern University in Illinois, said wearables were born out of the quantified self movement.
This is a movement that endorses using technology to track and analyze personal data for learning and improvement.
"Just the way when we're driving a vehicle, we see whether we're low on gas, and then we pass by the gas station and repump," Alshurafa told ABC News. "So, the idea was sort of can I see when I'm active? Not active? Can I see when I have poor health habits and then adjust accordingly. Did I have good quality asleep last night? If not, let me try to improve that."
He said there are benefits to wearables, mostly in the form of motivation to change behaviors.
A July 2022 study found wearables can empower patients and help with diagnosing conditions, changing behaviors and self-monitoring.
Additionally, a July 2019 study from the University of Florida in Gainesville found wearable devices can motivate and accelerate physical activity, although it did not find consistent improvement in health outcomes.
MORE: This is how wearables could catch early coronavirus symptoms
Dr. David McManus, chair and professor of medicine at UMass Chan Medical School and a digital medicine expert, said an example would be if someone wants to walk 10,000 steps a day and they wear an activity monitor that tells them they only walked 5,000 steps on a particular day. This might motivate that person to walk further to achieve their goal.
In turn, evidence shows people who are more physically active have fewer rates of heart attacks and are less likely to develop high blood pressure or obesity.
"The benefit would be if a person actually used that information to change their behavior," he told ABC News. "That would be the clearest use case of a person using a wearable to learn. … I won't say there's convincing concrete evidence that a wearable will prevent heart attacks -- I would be uncomfortable saying that -- but I do think it's reasonable on the basis of preliminary studies and observational studies, there is some potential benefit for certain types of people from wearing devices to get people motivated to change."
Alshurafa said clinicians can also receive more granular data about behaviors such as how much energy patients are expending and how many calories they are burning.
It's unclear if Kennedy's connections have played a role in his endorsements of wearables. U.S. surgeon general nominee Casey Means co-founded Levels, an app that allows people to track their food, along with biometric data like sleep and glucose monitoring, to see how their diet is impacting their health.
Additionally, her brother, Calley Means -- an adviser to Kennedy -- has a company that could benefit from more wearables in the world. His company, TruMed, allows people to use funds from Health Savings Accounts towards health products, such as fitness tracker watches.
There are also drawbacks. McManus said there is not a high level of evidence that shows wearables have benefits over the long term.
"One thing I've learned as a physician and researcher is it's really hard to get people to change their habits," he said. "So it's not so much that the sensors don't work, and it's not so much that they're inaccurate -- because there is plenty of data that shows that wearable devices can present really good, high-quality data -- but the missing link in the chain of wearables to good health is getting people to actually get off their couch and go be more active when they have a wearable them that they've been on the couch."
There are also privacy concerns because of the substantial amounts of data that wearables generate, as well as the potential for misuse.
McManus said if a database gets hacked, the data could be compromised and potentially used by a bad actor to steal additional personal information.
"The more data that's generated, the greater the risk," he said.
Authors of a JAMA Viewpoint article in 2019 said another risk is that data could be used against policyholders with higher premiums or to deny insurance.
Because wearables collect health information such as weight, calorie intake and blood pressure, insurance companies could use the data to increase costs, the authors said.
Alshurafa said not everyone needs to wear a wearable and it depends on the patient's condition and what they hope to achieve.
"We feel once their health improves, we then wean them off it," he said. "So, this notion that someone has to wear a wearable constantly -- well, I mean once the problem is solved, then hopefully there's no need for it."
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

CELFULL Unveils Celfavor NADH Microcapsules: A Breakthrough in Stability That Reshapes the Anti-Aging Industry
CELFULL Unveils Celfavor NADH Microcapsules: A Breakthrough in Stability That Reshapes the Anti-Aging Industry

Yahoo

time42 minutes ago

  • Yahoo

CELFULL Unveils Celfavor NADH Microcapsules: A Breakthrough in Stability That Reshapes the Anti-Aging Industry

CORAL SPRINGS, FL / / July 4, 2025 / CELFULL, a biotechnology company with over 25 years of expertise in anti-aging science, has announced a major breakthrough in longevity innovation: the global launch of Celfavor® NADH Microcapsules, a patented delivery system that resolves the century-long challenge of NADH instability. Journal papers related to NADH This revolutionary technology-protected by seven international invention patents across the U.S., China, Japan, Canada, and South Korea-delivers unprecedented improvements in stability, bioavailability, and targeted delivery, marking a new era in anti-aging therapeutics known as the "Microcapsule Age." To accelerate research across the globe, CELFULL has also launched its Global Research Sharing Program, offering free access to the Celfavor® NADH raw material to scientific institutions worldwide. Celfavor®NADH The only effective NADH - Celfavor ® NADH "The discovery of the therapeutic effect of stabilized NADH is more important to humankind than the discovery of antibiotics." noted Nobel Laureate Sir John Eccles, underscoring the importance of this innovation. NADH stands for "nicotinamide adenine dinucleotide (NAD) + hydrogen (H), often dubbed the "King of Anti-Aging Molecules," plays a central role in mitochondrial energy production, antioxidant defense, and the activation of longevity proteins. However, its inherent instability-sensitive to heat, light, oxygen, and stomach acid-has severely limited its clinical applications. Conventional NADH degrades by over 70% in one month at room temperature and must be stored at -20°C, making practical use difficult. 7 patents have been certified CELFULL's research team, led by its AI-powered Multi-Target Anti-Aging Institute, spent over a decade solving this problem. The result: Celfavor® NADH Microcapsules, a proprietary technology featuring 250-350μm microcapsules that protect NADH with a multi-core soluble shell made from food-grade materials. In stability tests simulating harsh conditions (40°C / 75% RH), traditional NADH retained only 3.5% of its activity after six months. By contrast, Celfavor® NADH maintained 98.3% activity-demonstrating over 6x shelf-life extension, even without refrigeration or light shielding. The stability of Celfavor® NADH microspheres The Celfavor® NADH Microcapsule system delivers innovation across four dimensions: 1. Enhanced Stability: Microcapsules shield NADH from air, moisture, light, and stomach acid, preserving its full potency in gastrointestinal conditions for up to 4 hours. 2. Targeted Release: Using AI-optimized wall material, the system enables "zero release in the stomach and sustained release in the intestine." Simulated intestinal studies show 24-hour continuous release, extending absorption time by 5-8x. 3. Superior Bioavailability: In human trials, a daily dose of 40mg led to a 98% increase in blood NAD⁺ levels, a 3.2x improvement over regular NADH. Performance also surpassed other NAD⁺ precursors like NMN and NR. 4. Formulation Flexibility: Unlike unstable NADH, Celfavor® NADH can be safely co-formulated with vitamins, coenzymes, or peptides in single or multi-ingredient capsules. Celfavor ® NADH microsphere advanced technology surpasses others Celfavor® NADH Microcapsules have been granted seven invention patents and passed all 12 safety evaluations, including cytotoxicity and long-term toxicity tests. It is currently the only NADH raw material globally to pass full-spectrum safety certification. The only globally certified raw material for toxicology and safety experiments "We are not just creating better products-we are building a platform for the future of longevity," said Dr. Juliane Hitzel, CEO of CELFULL. "With this microcapsule technology, we're launching new delivery systems for vitamins, peptides, and more. And by sharing our raw materials with global researchers, we're fostering a collaborative ecosystem that accelerates anti-aging science." From solving the NADH stability problem to advancing intelligent delivery systems, CELFULL's innovation signals a major milestone in human longevity science. As the Celfavor® NADH Microcapsule technology rolls out globally, the anti-aging industry enters a new chapter-one defined by precision, efficiency, and collaboration. For business cooperation or research partnerships, please contact:maggie@ | Email: maggie@ SOURCE: CELFULL View the original press release on ACCESS Newswire Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data

Maximise Your Portfolio's Returns with These 3 US Healthcare Stocks
Maximise Your Portfolio's Returns with These 3 US Healthcare Stocks

Yahoo

timean hour ago

  • Yahoo

Maximise Your Portfolio's Returns with These 3 US Healthcare Stocks

With persistent macro uncertainty and shifting market trends, healthcare remains one of the most defensive and fundamentally sound sectors for investors. The US healthcare industry continues to deliver both stability and long-term growth potential. In the latter half of 2025, these three healthcare stocks emerge as top picks for their compelling mix of innovation and favourable industry trends. Johnson & Johnson (J&J) is a global healthcare company with its core businesses in innovative medicine and MedTech. In the first quarter of 2025 (1Q 2025), J&J reported 2.4% year-on-year (YoY) increase in revenue, bringing in US$21.9 billion. This growth can be attributed to a strong revenue growth of 4.2% YoY in innovative medicine. A key driver for the rise is the 20.4% YoY in revenue growth in the oncology segment. This increase is due to medicine such as DARZALEX and ERLEADA experiencing share gains amid market growth.J&J's MedTech division recorded a strong 4.1% YoY revenue growth. The cardiovascular segment led this jump in revenue with a 17% YoY revenue growth. This growth is due to strong global procedure volumes and successful new product launches. The firm's internal forecast for sales of its key products by 2027/2028 is also higher than current market estimates. For instance, its pipeline product, the intravesical drug releasing system, is forecasted to have three times the product sales compared to current market estimates by 2027/ presents an opportunity for investors to capitalise on the potential upside which is not yet priced into the stock. This upside will be driven by J&J's internal forecasts, which signal confidence in its operations. Thermo Fisher is a top name in biopharmaceutical research, particularly in drug discovery and 1Q 2025, Thermo Fisher reported revenue of US$10.36 billion, along with organic revenue growth of 1% YoY. The firm's net profits climbed 13.5% YoY to US$1.5 billion in 1Q 2025. This strong growth was supported by the increased operational efficiencies with the partnership with the Chan Zuckerberg Institute for Advanced Biological partnership pioneers new technologies for improved human cell visualisation, providing scientists with better data insights and accelerating research cycles. In February 2025, Thermo Fisher also announced a US$4.1 billion acquisition of Solventum's Purification & Filtration Purification & Filtration business offerings enhance Thermo Fisher's current bioproduction services. This acquisition boosts Thermo Fisher's biologics production capabilities, thereby improving productivity. This deal also opens opportunities to cross-sell filtration and purification solutions alongside existing bioprocessing offerings. These developments demonstrate an effective strategic fit and may result in service margin expansion. UnitedHealth Group runs two primary businesses – UnitedHealthcare for healthcare insurance plans and Optum for technology-based healthcare services. UnitedHealth Group reported a 9.8% YoY increase in revenue in 1Q 2025, reaching US$109.6 billion. The company's net margin also improved to 5.7% in the same quarter. The previous year's quarter saw a net loss margin of 1.4%. The better performance was attributed to a strong performance for both UnitedHealthcare and Optum. In 1Q 2025, UnitedHealthcare's revenue grew by 12.2% YoY to US$84.6 billion. This growth was driven by a rise of 700,000 in the number of self-funded commercial plans sold. Another factor was the increased participation in senior and community-based offerings with 545,000 new members. In the same period, Optum saw an increase in revenue of 4.6% YoY to US$63.9 billion. This rise is led by a growth of Optum Rx which had an increase of 13 million scripts from new clients and deepening of existing relationships compared to 2024. Optum Insight also introduced artificial intelligence claim processing tools which increase productivity by over 20%. Moving forward, Optum Health announced its continued expansion of value-based care to serve 650,000 new patients in 2025. As the healthcare landscape transforms, these three companies offer stand-out opportunities amid uncertain markets. With these companies' blend of innovation and strong fundamentals, they provide a defensive anchor along with room for growth. These three stocks are well-positioned to deliver meaningful returns. It's a good idea to consider adding this trio into your buy watchlist of growth stocks. Generative AI is reshaping the stock market, but not in the way most investors think. It's not just about which companies are using AI. It's about how they're using it to unlock new revenue, dominate their markets, and quietly reshape the business world. Our latest FREE report 'How GenAI is Reshaping the Stock Market' breaks the hype down, so you can invest with greater clarity and confidence. Click here to download your copy today. Follow us on Facebook, Instagram and Telegram for the latest investing news and analyses! Disclosure: Gabriel Lim does not own shares in any of the companies mentioned. The post Maximise Your Portfolio's Returns with These 3 US Healthcare Stocks appeared first on The Smart Investor. Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store